The place of alpha interferon (IFN) therapy in the treatment of chronic myeloid leukaemia
(CML) is under intensive investigation at present. It is now established that as a single agent …

Interferon-A (IFN-A) is an effective agent in the treatment of chronic myelogenous leukemia
(CML). Hematologic remissions occur in the majority of patients with newly diagnosed …

In a prospective multicenter phase-II trial 80 patients with Philadelphia (Ph)-positive chronic
myelogenous leukemia (CML) were treated with recombinant interferon (IFN) α-2c …

A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …

Abstract Interferon-alpha (IFN-α) is a therapy of unquestionable efficacy in chronic myeloid
leukemia (CML) patients. The best dose of IFN-α in the treatment of CML still remains …

Several prospective randomized studies have shown that the treatment of chronic myeloid
leukemia with interferon-(IFN-) prolongs the survival by comparison with conventional …

Newly diagnosed chronic myelogenous leukaemia (CML) patients (n= 65) were treated with
interferon (IFN)‐α2b (5× 106 IU/d sc) combined with monthly courses of cytarabine (20 mg/d …

The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.
Retrospective analyses suggest that low doses are as effective as high doses, with less …

The purpose of this study was to evaluate the long-term outcome of interferon (IFN) alfa
treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia …

Ten years ago, alpha interferon (IFN-A) was introduced as a promising modality in the
management of patients with chronic myelogenous leukemia (CML). Since then, it has been …